TheraRadar
Data updated: May 26, 2026

Ixinity (coagulation factor ix (recombinant))

Approved 2015-04-28
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2015-04-28
Routes
Intravenous
Dosage Forms
For Injection

Companies

Medexus Pharma, Inc.
Active Ingredient: Coagulation Factor IX (Recombinant) , Coagulation Factor IX (Recombinant) , Coagulation Factor IX (Recombinant) , Coagulation Factor IX (Recombinant) , Coagulation Factor IX (Recombinant) , Coagulation Factor IX (Recombinant)

Ixinity Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2015 to 2015
Apr 2015 ORIGINAL
Update · CBER biologic (Purple Book)

What Ixinity Treats

1 FDA approvals

Originally approved for its first indication in 2015 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Ixinity FDA Label Details

Track Ixinity with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: BLA125426 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.